Astrazeneca (AZN) Enterprise Value (2009 - 2026)

Astrazeneca has reported Enterprise Value for 18 years, with the latest figure at $288.7 billion in Q2 2026.

• On a quarterly basis, Enterprise Value rose 38.03% year-over-year to $288.7 billion in Q2 2026; TTM through Jun 2026 was $288.7 billion, a 38.03% increase from a year earlier, with the FY2025 full-year figure at $278.8 billion, up 41.16% from the prior year.
• Enterprise Value was $288.7 billion for Q2 2026 at Astrazeneca, down from $297.8 billion in the prior quarter.
• The five-year high for Enterprise Value was $297.8 billion in Q1 2026, with the low at $165.4 billion in Q3 2022.
• Average Enterprise Value over 5 years is $221.8 billion, with a median of $208.9 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value soared 62.75% in 2022, then decreased 10.83% in 2025.
• Over 5 years, Enterprise Value stood at $203.9 billion in 2022, then declined by 2.72% to $198.3 billion in 2023, then retreated by 0.4% to $197.5 billion in 2024, then surged by 41.16% to $278.8 billion in 2025, then gained by 3.54% to $288.7 billion in 2026.
• The last three Enterprise Value figures came in at $288.7 billion (Q2 2026), $297.8 billion (Q1 2026), and $278.8 billion (Q4 2025), per Business Quant data.